Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 17 June 2022, including: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "BIO 2022 Notebook: How Is Industry Faring In Turbulent Times?" - Scrip, 13 Jun, 2022.)

(Also see "BIO 2022 Notebook: Staying Afloat In Rough Waters" - Scrip, 14 Jun, 2022.)

(Also see "Lilly's Olumiant Is First Drug FDA Approved For Alopecia Areata" - Scrip, 13 Jun, 2022.)

(Also see "Argenx Enters Japan With Smooth Approval – How Was It Possible?" - Scrip, 10 Jun, 2022.)

(Also see "BTK Inhibitors Are The Next Big Race In MS" - Scrip, 9 Jun, 2022.)

 

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC146576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel